AbbVie Announces $10.9 Billion Acquisition of Apogee Therapeutics
Pharmaceutical giant AbbVie announced a planned acquisition of Apogee Therapeutics for $10.9 billion, offering a 49% premium over the latter's closing price. The deal aims to bolster AbbVie’s immunology portfolio with Apogee’s promising drug zumilokibart, which could compete with Regeneron and Sanofi’s Dupixent in treating atopic dermatitis.
Tickers: $ABBV $APGE $REGN $SNY